Results 11 to 20 of about 101,271 (322)

Clinically Relevant Drug Interactions with Monoamine Oxidase Inhibitors. [PDF]

Health Psychol Res, 2022
Monoamine oxidase inhibitors (MAOI) are a class of drugs that were originally developed for the treatment of depression but have since been expanded to be used in management of affective and neurological disorders, as well as stroke and aging-related ...
Edinoff AN, Swinford CR, Odisho AS, Burroughs CR, Stark CW, Raslan WA, Cornett EM, Kaye AM, Kaye AD.   +8 more
europepmc   +3 more sources

Amphetamine Derivatives as Monoamine Oxidase Inhibitors. [PDF]

Front Pharmacol, 2019
Amphetamine and its derivatives exhibit a wide range of pharmacological activities, including psychostimulant, hallucinogenic, entactogenic, anorectic, or antidepressant effects.
Reyes-Parada M, Iturriaga-Vasquez P, Cassels BK.   +2 more
europepmc   +3 more sources

Role of Monoamine Oxidase Activity in Alzheimer’s Disease: An Insight into the Therapeutic Potential of Inhibitors

Molecules, 2021
Despite not being utilized as considerably as other antidepressants in the therapy of depression, the monoamine oxidase inhibitors (MAOIs) proceed to hold a place in neurodegeneration and to have a somewhat broad spectrum in respect of the treatment of ...
Tapan Behl, Dapinder Kaur, Aayush Sehgal, Sukhbir Singh, Neelam Sharma, Gokhan Zengin, Felicia Liana Andronie-Cioara, Mirela Marioara Toma, Simona Bungau, Adrian Gheorghe Bumbu   +9 more
doaj   +2 more sources

Quercetin and Related Chromenone Derivatives as Monoamine Oxidase Inhibitors: Targeting Neurological and Mental Disorders. [PDF]

Molecules, 2019
Monoamine oxidase inhibitions are considered as important targets for the treatment of depression, anxiety, and neurodegenerative disorders, including Alzheimer’s and Parkinson’s diseases.
Dhiman P, Malik N, Sobarzo-Sánchez E, Uriarte E, Khatkar A.   +4 more
europepmc   +3 more sources

Design and Synthesis of Novel and Potent Monoamine Oxidase Inhibitors [PDF]

CHIMIA, 1995
Reversible and selective monoamine oxidase-A inhibitors (RIMA's) like moclobemide (Aurorix®) have rehabilitated the use of MAO inhibitors as drugs of choice in depression.
Branca, Quirico, Jakob-Røtne, Roland, Kettler, Rolf, Röver, Stephan, Scalone, Michelangelo   +4 more
core   +6 more sources

Structure-Activity Relationship Analysis of 3-Phenylcoumarin-Based Monoamine Oxidase B Inhibitors

Frontiers in Chemistry, 2018
Monoamine oxidase B (MAO-B) catalyzes deamination of monoamines such as neurotransmitters dopamine and norepinephrine. Accordingly, small-molecule MAO-B inhibitors potentially alleviate the symptoms of dopamine-linked neuropathologies such as depression ...
Sanna Rauhamäki, Pekka A. Postila, Sanna Niinivehmas, Sami Kortet, Sami Kortet, Emmi Schildt, Emmi Schildt, Mira Pasanen, Elangovan Manivannan, Elangovan Manivannan, Mira Ahinko, Pasi Koskimies, Niina Nyberg, Pasi Huuskonen, Elina Multamäki, Markku Pasanen, Risto O. Juvonen, Hannu Raunio, Juhani Huuskonen, Olli T. Pentikäinen, Olli T. Pentikäinen   +20 more
doaj   +2 more sources

Monoamine oxidase inhibitors. [PDF]

BMJ, 1968
Amberly Johnson
  +13 more sources

Monoamine Oxidase Inhibitors: A Review of Their Anti-Inflammatory Therapeutic Potential and Mechanisms of Action. [PDF]

Front Pharmacol, 2021
Chronic inflammatory diseases are debilitating, affect patients’ quality of life, and are a significant financial burden on health care. Inflammation is regulated by pro-inflammatory cytokines and chemokines that are expressed by immune and non-immune ...
Ostadkarampour M, Putnins EE.
europepmc   +2 more sources

Droperidol and Monoamine-oxidase Inhibitors [PDF]

BMJ, 1966
G. N. Penlington
openaire   +4 more sources

Piperidine: A Versatile Heterocyclic Ring for Developing Monoamine Oxidase Inhibitors. [PDF]

ACS Omega, 2023
Jayan J, Chandran N, Thekkantavida AC, Abdelgawad MA, Ghoneim MM, Shaker ME, Uniyal P, Benny F, Zachariah SM, Kumar S, Kim H, Mathew B.   +11 more
europepmc   +2 more sources